Aligos Therapeutics (ALGS) Other Accumulated Expenses (2019 - 2026)

Aligos Therapeutics (ALGS) has 8 years of Other Accumulated Expenses data on file, last reported at $1.5 million in Q1 2026.

• Quarterly Other Accumulated Expenses fell 41.56% year-over-year to $1.5 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $1.5 million (down 41.56% YoY) and the FY2025 annual result came in at $3.2 million, down 39.6% from the prior year.
• Other Accumulated Expenses eased to $1.5 million in Q1 2026, from $3.2 million in the prior quarter.
• In the past five years, Other Accumulated Expenses ranged from a high of $6.6 million in Q4 2023 to a low of $856000.0 in Q2 2022.
• A 5-year average of $2.7 million and a median of $2.5 million in 2025 frame the typical range for Other Accumulated Expenses.
• Annual changes were most pronounced in 2023 — Other Accumulated Expenses jumped 350.31% — and 2026, when it slumped 41.56%.
• Tracing ALGS's Other Accumulated Expenses over 5 years: stood at $1.5 million in 2022, then surged by 350.31% to $6.6 million in 2023, then retreated by 18.91% to $5.4 million in 2024, then plunged by 39.6% to $3.2 million in 2025, then tumbled by 54.17% to $1.5 million in 2026.
• The last three Other Accumulated Expenses figures came in at $1.5 million (Q1 2026), $3.2 million (Q4 2025), and $4.8 million (Q3 2025), per Business Quant data.